Teva execs claim mixed winning streak in pricey opioids court battle — as permanent peace remains elusive

Teva execs turned up for the Q4 call with analysts to go deep into the numbers, but it wasn’t long before the litigation around opioids took center stage in the Q&A.

CEO Kåre Schultz addressed the recent court decisions in the US related to the pharma’s role in the US opioid epidemic — and how there have been mixed results in different courts, specifically California, Oklahoma and in New York